A Real-World Study About Anemia in Chronic Kidney Disease in China（DASHENG）
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Anemia in Chronic Kidney Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
An In-Depth Analysis of the Present Diagnostic and Therapeutic Landscape for Renal Anemia in China's Real-World Clinical Environment: A Multicenter Retrospective Cohort Investigation（DASHENG Study）
Overview
Anemia affects the quality of life of CKD patients and increases the risk of CKD progression. we conducted a real-world study on patients with anemia in CKD to analyze the disease characteristics and treatment in Chinese patients with CKD-anemia.
Detailed description
Anemia adversely affects the quality of life of CKD patients and increases the risk of CKD progression.
This study utilize data from approximately 20 medical centers across China. It aims to:
1. Analyze the disease characteristics, current diagnostic and treatments in Chinese patients with CKD-anemia. 2. Evaluate the safety and efficacy profiles of different drugs used for CKD-anemia. 3. Explore the direct medical costs associated with CKD-anemia management within real-world clinical practice in China.
Primary outcome measures
- Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China. [Time frame: 20230101-20241231]
- Incidence of Adverse Events according to CTCAE 5.0 (Safety profile of different anemia medications in CKD patients with anemia.) [Time frame: 20230101-20241231]
Secondary outcome measures (2)
- Analyze the efficacy of different anemia drugs in CKD patients with anemia. [Time frame: 20230101-20241231]
- Explore the economic burden of anemia in CKD patients [Time frame: 20230101-20241231]
Eligibility criteria
Inclusion Criteria: CKD patients will be defined as those meeting any of the following criteria during the observation period:
- diagnosis of CKD (e.g., "%chronic kidney disease%", "%chronic nephropathy%", "%renal failure%", "%nephritis%" for complete ICD-9/10 code mapping\*)
- record of hemodialysis (HD) or peritoneal dialysis (PD) (refer to Attachment 2 for dialysis identification algorithms)
- ≥2 eGFR measurements <60 mL/min/1.73m² (calculated using CKD-EPI equation) with ≥3-month interval (excluding acute kidney injury)
Exclusion criteria
- Non-renal anemia due to trauma, traffic accidents, major hemorrhage, or other confirmed etiologies (e.g., acute hemorrhagic anemia, nutritional deficiency anemia, hemolytic anemia);
- Diagnosis of acute kidney disease (AKD) without chronic kidney disease (CKD) comorbidity;
- Incomplete critical data elements (including age, sex, or visit dates).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- First Affiliated Hospital, Sun Yat-Sen University — Guangzhou
Identifiers
NCT: NCT07098416 · IIT-2025-121